Drug Profile
PASylated granulocyte macrophage colony stimulating factor - XL-protein GmbH
Alternative Names: PAS-GMCSF; xl-150Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator XL-protein GmbH
- Class Antineoplastics; Glycoproteins; Granulocyte-macrophage colony-stimulating factors
- Mechanism of Action Granulocyte-macrophage colony stimulating factor replacements; Haematopoiesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Cancer in Germany
- 09 Aug 2016 PASylated granulocyte macrophage colony stimulating factor - XL-protein GmbH is available for licensing as of 09 Aug 2016. http://www.xl-protein.com/
- 09 Aug 2016 Early research in Cancer in Germany (unspecified route)